肿瘤生物治疗新进展(2)
[4] Wang Y, Xu HX, Lu MD, et al. Expression of thymidine kinase mediated by a novel non-viral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells. World J Gastroenterol,2008,14(2):224-230.
[5] Chen F, Wang T, Wang J, et al. Levistolide overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol Sin,2008,29(4):458-464.
[6] Osada T, Clav TM, Woo CY, et al. Dendritic cell-based immunotherapy. Int Rev Immunol,2006,25(5-6):377-413.
[7] Old LJ. Cancer vaccines: an overview. Cancer Immun,2008,8(1):1.
[8] Naka T, Iwahashi M, Nakamura M, et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci,2008,99(2):407-413.
[9] Tandle A, Libutti SK. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clin Adv Hematol Oncol,2003,1(1):41-48.
[10] Kumar CC. Integrin αγβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets,2003,4:123-131.
[11] Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer Nat Rev Cancer,2003,3(12 )：895-902.
[12] Zhou S, Schuetz JD, Bunting K D, et al. The ABC trans-porter Bcrpl /ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med, 2001,7(9):1 028-1034., http://www.100md.com(林 垚 李承博 侯东泽)
[5] Chen F, Wang T, Wang J, et al. Levistolide overcomes P-glycoprotein-mediated drug resistance in human breast carcinoma cells. Acta Pharmacol Sin,2008,29(4):458-464.
[6] Osada T, Clav TM, Woo CY, et al. Dendritic cell-based immunotherapy. Int Rev Immunol,2006,25(5-6):377-413.
[7] Old LJ. Cancer vaccines: an overview. Cancer Immun,2008,8(1):1.
[8] Naka T, Iwahashi M, Nakamura M, et al. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA. Cancer Sci,2008,99(2):407-413.
[9] Tandle A, Libutti SK. Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clin Adv Hematol Oncol,2003,1(1):41-48.
[10] Kumar CC. Integrin αγβ3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets,2003,4:123-131.
[11] Pardal R, Clarke MF, Morrison SJ. Applying the principles of stem-cell biology to cancer Nat Rev Cancer,2003,3(12 )：895-902.
[12] Zhou S, Schuetz JD, Bunting K D, et al. The ABC trans-porter Bcrpl /ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med, 2001,7(9):1 028-1034., http://www.100md.com(林 垚 李承博 侯东泽)